Motif Bio plc (LON: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, has announced today that the Company has received a Complete Response Letter from the U.S. Food..
Motif Bio plc (LON:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, has today announced that the Company has received a Notice of Allowance from the United States Patent..
Motif Bio plc (LON:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today provided an update on the status and timeline for submission of its New Drug Application (NDA)..
Motif Bio plc (LON:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company will participate in the following event: Cantor Antibiotics Summit January 17,..
Motif Bio plc (LON:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that new pre-clinical data with its investigational drug candidate iclaprim were presented today during..
Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced positive topline results from REVIVE-2, a global Phase 3 clinical trial evaluating the investigational..
Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the last patient has completed the treatment phase in REVIVE-2, the second Phase..
Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that it has amended the terms of its consultancy agreement with Amphion Innovations plc...
Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that three abstracts have been accepted for poster presentations at the Infectious Diseases Week..
Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that Dr. David Huang, Chief Medical Officer at Motif Bio, has been invited to..
Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company will present at BIO 2017 being held at the San Diego..
Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today its intention to raise approximately £19.4 million (US$25 million), before expenses, by way of..
Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces the appointment of Dr. Craig T. Albanese to the Company’s Board as Non-Executive Director with..
Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, have announced today positive topline results from REVIVE-1, a global Phase 3 clinical trial of its..
Motif Bio plc (LON: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the last patient has finished the treatment phase in REVIVE-1, the Phase..
Northland Capital Partners Head of Research Vadim Alexandre caught up with DirectorsTalk for an exclusive interview to discuss ImmuPharma PLC (LON:IMM) Q1: Now Vadim, Northland have just been appointed..
Zeus Capital Healthcare Research Director Dr Gary Waanders caught up with DirectorsTalk for an exclusive interview to discuss Motif Bio PLC (LON:MTFB) Q1: Now, you updated your coverage on..
Motif Bio Plc (LON:MTFB) is the topic of conversation when DirectorsTalk caught up with Dr Gary Waanders the Director of Healthcare Research at Zeus Capital. Gary covers the highlights for..
Motif Bio plc (LON:MTFB, NASDAQ:MTFB), is a late clinical stage antibiotic development company. The company completed its IPO on NASDAQ in November last year raising $25m before expenses. With the..
Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that Robert Dickey IV has been appointed as Chief Financial Officer. Mr. Dickey is an..
